false
0000811641
0000811641
2025-10-07
2025-10-07
FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 7, 2025
|
ImmuCell Corporation
|
|
(Exact name of registrant as specified in its charter)
|
|
Delaware
|
|
001-12934
|
|
01-0382980
|
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
56 Evergreen Drive Portland, Maine
|
|
04103
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code 207-878-2770
| |
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
| |
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| |
|
|
| |
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| |
|
|
| |
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| |
|
|
| |
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, $0.10 par value per share
|
|
ICCC
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition
On October 7, 2025 ImmuCell Corporation (the "Company") issued a press release announcing its preliminary, unaudited product sales for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
|
99.1
|
Press Release of the Company dated October 7, 2025.
|
|
104
|
Cover page Interactive Data File (embedded within the Inline XBRL document)
|
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
IMMUCELL CORPORATION
|
| |
|
|
Date: October 7, 2025
|
By:
|
/s/ Michael F. Brigham
|
| |
|
Michael F. Brigham
|
| |
|
President, Chief Executive Officer and Principal Financial Officer
|
| |
|
|
|
Date: October 7, 2025
|
By:
|
/s/ Timothy C. Fiori
|
| |
|
Timothy C. Fiori
|
| |
|
Chief Financial Officer
|
2
Exhibit Index
|
Exhibit No.
|
|
Description
|
| |
|
|
|
99.1
|
|
Press Release of the Company dated October 7, 2025.
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
3
